SARS-CoV-2 variants of concern exhibit reduced sensitivity to live-virus neutralization in sera from CoronaVac vaccinees and naturally infected COVID-19 patients

Cohort

Patients were confirmed to be infected by RT-PCR on nasopharyngeal and throat swab specimens through amplification of SARS-CoV-2 ORF1AB and N target gene fragments (Sansure Biotech Inc, Changsha, PR China). Details regarding patient demographics can be found in Table 1.

Virus variants and culture

The wildtype SARS-CoV-2 virus (SARS-CoV-2/human/THA/LJ07_P3/2020), was isolated from a nasopharyngeal swab sample from an RT-PCR confirmed COVID-19 patient provided by Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand. African green monkey (Cercopithecus aethiops) kidney epithelial cells (Vero cells) (ATCC CCL-81) were used for virus isolation and a Vero cell derivative (Vero E6 cells) (ATCC CRL-1586) was used for virus propagation.

The B.1.1.7 (SARS-CoV-2/human/THA/NH657_P3/2021) and B.1.617.2 (SARS-CoV-2/human/THA/OTV007_P3/2021) variants were isolated from nasopharyngeal swab samples from RT-PCR confirmed COVID-19 patients provided by Ramathibodi Chakri Naruebodindra Hospital (Chakri Naruebodindra Medical Institute), Samut Prakan, Thailand. The B.1.351 variant (SARS-CoV-2/human/THA/NH088_P3/2021) was isolated from a nasopharyngeal swab sample from an RT-PCR confirmed COVID-19 patient provided by the Division of Genomic Medicine and Innovation Support, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand. For B.1.1.7, B.1.617.2 and B.1.351, Vero E6 cells were used for both virus isolation and propagation.

Vero cells were cultured in minimum essential medium (MEM) (Gibco, Detroit, MI, USA) and Vero E6 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco). Virus isolation and propagation were conducted in a certified BSL3 facility at the Microbiology Department, Faculty of Science, Mahidol University, Bangkok, Thailand.

Sequencing

Nucleic acid was extracted from 200 µl culture supernatant using the GenTiTM32 Automatic Extraction System (Advanced Viral DNA/RNA Extraction Kit) according to the manufacturer’s instructions, followed by library preparation using the ARTIC SARS-CoV-2 sequencing protocol (https://dx.doi.org/10.17504/protocols.io.bgxjjxkn). Prepared libraries were sequenced (paired-end) with single indexing on a MiSeq (Illumina) sequencer at the Center of Medical Genomics, Ramathibodi Hospital, Thailand.

The sequence of a reference SARS-CoV-2 (NCBI Reference Sequence: NC_045512.2) was used as a query sequence to pull SARS-CoV-2 reads from the Next Generation Sequencing read datasets by BLASTn. The BLASTn results were then used to construct alignments of the reads. After manual curation, the consensus sequences were determined according to the top 80% most frequent nucleotide residues at each position.

Live-virus microneutralization

Sera were heat inactivated at 56°C for 30 min then two-fold serially diluted starting from 1:10. Equal volumes of SARS-CoV-2 were spiked into the serial dilutions at an infectious dose of 100 TCID₅₀ (50% tissue culture infectious dose) and incubated for 1h at 37°C. Vero E6 cells (ATCC USA) were pre-seeded in Dulbecco’s modified Eagle medium (DMEM) supplemented with 2% fetal bovine serum (FBS), 100 U/mL penicillin, and 0.1 mg/mL of streptomycin. 100 µL of the virus-serum mixtures at different dilutions were added to 1×10₄ pre-seeded Vero E6 cell monolayers in duplicate on a 96-well microtiter plate, then incubated for 2 days at 37°C and 5% CO₂. The last two columns contained the virus control, cell control, and virus back-titration. Medium was discarded and cells were fixed and permeabilized with ice-cold 1:1 methanol/acetone fixative for 20 min at 4°C. Cells were washed thrice with 1xPBS containing 0.05% Tween 20 then blocked with a blocking buffer consisting of 2% bovine serum albumin (BSA) and 0.1% Tween 20 in 1×PBS for 1h. After washing 3 more times with wash buffer, SARS-CoV/SARS-CoV-2 nucleocapsid mAb (Sino Biological, Cat#40143-R001) diluted 1:5000 in 1×PBS containing 0.5% BSA and 0.1% Tween 20 was added to each well and incubated for 2h at 37°C. Detection antibody was removed by washing the plate 3 more times, then 1:2000 HRP-conjugated goat anti-rabbit polyclonal antibody (Dako, Denmark A/S, Cat#P0448) was added and the plate incubated at 37°C for 1h. Plates were washed thrice more, then TMB substrate was added (KPL, Cat#5120-0075) for 10 min. The reaction was stopped with 1N HCl. Absorbance was measured at 450 and 620 nm (reference wavelength) with an ELISA plate reader (Tecan Sunrise).

The average optical density (O.D.) at 450 and 620 nm were determined for virus control and cell control wells, and the neutralizing endpoint was determined by 50% specific signal calculation. The virus neutralizing endpoint titer of each serum was expressed as the reciprocal of the highest serum dilution with an OD value less than X which was calculated as follows:

Sera which tested negative at 1:10 dilution were assigned a titer of <10. Sera were considered positive if neutralization titer was ≥20. Live SARS-CoV-2 viruses at passage 3 or 4 and Vero E6 cells at 20 maximum passages were employed. Activities with live viruses were carried out in a certified BSL-3 facility.

Data and statistical analyses

The relationship between levels of (log-10 transformed) IgG titer, the immunogenic elicitor, serum collection date, age, and gender, was modelled using a linear model: for immunogenic elicitor i,y_IgG[i] is (log-10 transformed) IgG titer; x_date is the serum collection date in days (from latest vaccine dose or from illness onset); x_sex indicates if the participant was a male; x_age is the age of the participant in years; β_elicitor[i] is the effect of the elicitor, while, β_date, β_sex, β_age and are the effects of the serum collection date, gender, and age, on the level of IgG titer respectively, and e_[i] is the residual error term. e_[i] are assumed to be independently and identically distributed (i.i.d.) 𝒩 (0, σ²). The lm function as implemented in the R library stats (v 4.0.4) was used to fit the model to the data. The level of IgG titer among the three cohort groups were compared using the Tukey method, adjusted for serum collection date, age, and sex, using the emmeans function as implemented in the R library emmeans (v 1.6.1).

By using the lmer function implemented in the R library lme4, a linear mixed model was fitted to the data to model the levels of NAb titers elicited by the three immunogenic elicitors against the four virus strains, accounting for the IgG titer, participant age and sex, as well as the variation among subjects: for immunogenic elicitor i virus j and subject k,y_NAb[i][j][k] is (log-10 transformed) NAb titer; γ_elicitor[i] is the effect of elicitor, γ_virus[j] is the effect of virus; γ_{elicitor[i] virus[j]} is the effect of the interaction between the elicitor and the virus; x_{sex [k]} indicates if the participant k was a male; x_age[k] is the age of the participant k in years; x_IgG[k] is (log-10 transformed) IgG titer of participant k; γ_sex, γ_age, γ_IgG and are the fixed effects of the gender, age, and IgG titer on the level of NAb titer, respectively; the varying coefficient δ_[k] accounts for the random effect raising form the fact that serum form a single participant k was used to measure NAb titers against the four virus strains under the study. δ_[k] is assumed to be normally distributed with mean zero and variant , where indicates the overall variation of the model intercepts among the participants, and similarly e_[i][j][k] ∼i. i. d. 𝒩(0, σ²). For each elicitor group, NAb titer values among virus groups were compared based on the model using the Tukey method with the emmeans function as implemented in the R library emmeans (v 1.6.1) (Figure 2A). The same analysis was performed to compare NAb titer values among cohort groups nested within virus strain (Figure 2B).